ZA200501856B - Pyrazolopyridines and methods of making and using the same - Google Patents
Pyrazolopyridines and methods of making and using the same Download PDFInfo
- Publication number
- ZA200501856B ZA200501856B ZA200501856A ZA200501856A ZA200501856B ZA 200501856 B ZA200501856 B ZA 200501856B ZA 200501856 A ZA200501856 A ZA 200501856A ZA 200501856 A ZA200501856 A ZA 200501856A ZA 200501856 B ZA200501856 B ZA 200501856B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- compound
- composition
- substance
- heterocycloalkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 48
- 150000005229 pyrazolopyridines Chemical class 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 127
- 150000001875 compounds Chemical class 0.000 claims description 70
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- -1 hydroxy, amino Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 125000004414 alkyl thio group Chemical group 0.000 claims description 28
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 24
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 23
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 12
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 230000003176 fibrotic effect Effects 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 10
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 210000002744 extracellular matrix Anatomy 0.000 claims description 10
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 230000019491 signal transduction Effects 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 125000003435 aroyl group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical group NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 7
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 7
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 7
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims description 6
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims description 6
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 6
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 6
- 239000004202 carbamide Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 claims description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 6
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical group OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 2
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 42
- 239000000126 substance Substances 0.000 claims 40
- 230000002401 inhibitory effect Effects 0.000 claims 16
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 206010027476 Metastases Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 230000037390 scarring Effects 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- WBYIDWODCBKPKM-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-3-(2-methylsulfanylpyrimidin-4-yl)pyrazolo[1,5-a]pyridine Chemical compound CSC1=NC=CC(C2=C3C=CC=CN3N=C2C=2N=C(C)C=CC=2)=N1 WBYIDWODCBKPKM-UHFFFAOYSA-N 0.000 claims 1
- FSMFIPLMGNQWQW-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C=2C(=C3N=CC=CN3N=2)C=2N=C(N)N=CC=2)=N1 FSMFIPLMGNQWQW-UHFFFAOYSA-N 0.000 claims 1
- VENUMYHILKBIGQ-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-c]pyrimidin-3-yl]pyrimidin-2-amine Chemical compound CC1=CC=CC(C=2C(=C3C=CN=CN3N=2)C=2N=C(N)N=CC=2)=N1 VENUMYHILKBIGQ-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010004664 Biliary fibrosis Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000007659 Fibroadenoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010059616 Activins Proteins 0.000 description 10
- 102000005606 Activins Human genes 0.000 description 10
- 239000000488 activin Substances 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 4
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 3
- 102400000401 Latency-associated peptide Human genes 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- NWGPLYYBECWONP-UHFFFAOYSA-N (carbamoylamino) hydrogen sulfate Chemical compound NC(=O)NOS(O)(=O)=O NWGPLYYBECWONP-UHFFFAOYSA-N 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 101800001155 Latency-associated peptide Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000007614 Thrombospondin 1 Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009681 mesenchymal cell proliferation Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40881102P | 2002-09-06 | 2002-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501856B true ZA200501856B (en) | 2006-04-26 |
Family
ID=31978684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501856A ZA200501856B (en) | 2002-09-06 | 2005-03-03 | Pyrazolopyridines and methods of making and using the same |
Country Status (20)
Country | Link |
---|---|
US (1) | US7691865B2 (is) |
EP (1) | EP1551398A4 (is) |
JP (1) | JP2006502165A (is) |
KR (1) | KR20050057235A (is) |
CN (1) | CN1694698A (is) |
AR (1) | AR041207A1 (is) |
AU (1) | AU2003268447B2 (is) |
BR (1) | BR0314053A (is) |
CA (1) | CA2497970A1 (is) |
EA (1) | EA009441B1 (is) |
GE (1) | GEP20074125B (is) |
IS (2) | IS7726A (is) |
MX (1) | MXPA05002443A (is) |
NO (1) | NO20051503D0 (is) |
NZ (1) | NZ539069A (is) |
PL (1) | PL375699A1 (is) |
RS (1) | RS20050200A (is) |
UA (1) | UA80295C2 (is) |
WO (1) | WO2004022054A1 (is) |
ZA (1) | ZA200501856B (is) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004194A1 (ja) * | 2004-07-02 | 2006-01-12 | Nishimoto, Tomo | TGFβ2を標的としたアルツハイマー病治療薬のスクリーニング法 |
AU2005295734A1 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP2918288B1 (en) | 2006-10-03 | 2017-08-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
WO2009039387A1 (en) * | 2007-09-20 | 2009-03-26 | Wyeth | Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
AU2009224209B2 (en) * | 2008-03-14 | 2015-01-22 | Otsuka Pharmaceutical Co., Ltd. | MMP-2 and/or MMP-9 inhibitor |
CN101544634B (zh) * | 2008-03-27 | 2011-08-10 | 天津药物研究院 | 2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途 |
EP2402344A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
EP2402335A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
DK2970205T3 (da) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
SG11201601138PA (en) | 2013-08-23 | 2016-03-30 | Neupharma Inc | Certain chemical entities, compositions, and methods |
WO2015097121A1 (en) | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
CN106132967B (zh) * | 2014-03-27 | 2019-05-28 | 詹森药业有限公司 | 作为ros1抑制剂的化合物 |
JP7101165B2 (ja) * | 2016-08-15 | 2022-07-14 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
CN112707902B (zh) * | 2020-03-23 | 2022-04-15 | 杭州阿诺生物医药科技有限公司 | TGF-β受体抑制剂 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940486A (en) * | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
US4302464A (en) | 1980-10-16 | 1981-11-24 | Pfizer Inc. | Imidazolylpyridine therapeutic agents |
US4686231A (en) * | 1985-12-12 | 1987-08-11 | Smithkline Beckman Corporation | Inhibition of 5-lipoxygenase products |
JP2753659B2 (ja) * | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
US5593991A (en) * | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
US6369068B1 (en) * | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
EP0846699A1 (en) | 1995-06-29 | 1998-06-10 | Fujisawa Pharmaceutical Co., Ltd. | Substance wf16616, process for production thereof, and use thereof |
US5792778A (en) * | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US5837719A (en) | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
ZA9610687B (en) * | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
HUP9902460A3 (en) | 1996-01-11 | 2000-03-28 | Smithkline Beecham Corp | Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them |
ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
JP2000504013A (ja) | 1996-02-01 | 2000-04-04 | スミスクライン・ビーチャム・コーポレイション | エンドセリンレセプターアンタゴニスト |
EP1005343A1 (en) * | 1996-03-08 | 2000-06-07 | Smithkline Beecham Corporation | Use of csaid?tm compounds as inhibitors of angiogenesis |
EP0888335A4 (en) | 1996-03-13 | 2002-01-02 | Smithkline Beecham Corp | NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES |
US6235760B1 (en) * | 1996-03-25 | 2001-05-22 | Smithkline Beecham Corporation | Treatment for CNS injuries |
JP2000507558A (ja) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
US6080870A (en) * | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5880140A (en) * | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0906307B1 (en) * | 1996-06-10 | 2005-04-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
PT948495E (pt) * | 1996-11-19 | 2004-08-31 | Amgen Inc | Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5939439A (en) * | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ES2202840T3 (es) | 1997-04-24 | 2004-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Imidazoles sustituidos utiles en el tratamiento de enfermedades inflamatorias. |
US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
JP2002502379A (ja) * | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼインヒビターとしての3(5)−ヘテロアリール置換ピラゾール |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
CA2293436C (en) | 1997-06-12 | 2010-10-26 | Rhone-Poulenc Rorer Limited | Imidazolyl-cyclic acetals as tnf inhibitors |
AU7966198A (en) | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
KR20010014288A (ko) * | 1997-06-30 | 2001-02-26 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 염증성 질환의 치료에 유용한 2-치환된 이미다졸 |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
TW517055B (en) * | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
US6562832B1 (en) * | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7301021B2 (en) * | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
AR017219A1 (es) | 1997-12-19 | 2001-08-22 | Smithkline Beecham Corp | Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento |
WO2000010563A1 (en) | 1998-08-20 | 2000-03-02 | Smithkline Beecham Corporation | Novel substituted triazole compounds |
ATE258055T1 (de) * | 1998-11-04 | 2004-02-15 | Smithkline Beecham Corp | Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine |
US6239279B1 (en) * | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
JP4632544B2 (ja) * | 1998-12-25 | 2011-02-16 | あすか製薬株式会社 | アミノピラゾール誘導体 |
WO2000059902A2 (en) * | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
US6465493B1 (en) | 1999-04-09 | 2002-10-15 | Smithkline Beecham Corporation | Triarylimidazoles |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
KR100697585B1 (ko) * | 1999-06-03 | 2007-03-22 | 아스카 세이야쿠 가부시키가이샤 | 치환 피라졸 화합물 |
EP1196167B1 (en) * | 1999-07-02 | 2006-04-19 | Stuart A. Lipton | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
US20030109428A1 (en) * | 1999-12-01 | 2003-06-12 | John Bertin | Novel molecules of the card-related protein family and uses thereof |
EP1244672B1 (en) * | 1999-12-21 | 2005-07-20 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
ATE266022T1 (de) | 2000-03-06 | 2004-05-15 | Smithkline Beecham Plc | Imidazol derivate als raf kinase inhibitoren |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
JP4722318B2 (ja) * | 2000-06-05 | 2011-07-13 | ローム株式会社 | チップ抵抗器 |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
EP1289523A1 (en) * | 2000-06-01 | 2003-03-12 | Merck & Co., Inc. | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
US6599926B2 (en) | 2000-06-23 | 2003-07-29 | Bristol-Myers Squibb Company | Heteroaryl-phenyl substituted factor Xa inhibitors |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
KR100876069B1 (ko) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
WO2002024680A1 (en) * | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Imidazole derivatives as raf kinase inhibitors |
US7041686B2 (en) | 2000-10-18 | 2006-05-09 | Scott Beers | Substituted imidazoles useful in the treatment of inflammatory diseases |
US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
US6603005B2 (en) * | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
EP1349851A4 (en) * | 2000-11-16 | 2004-09-08 | Smithkline Beecham Corp | COMPOUNDS |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
EP1343779B1 (en) * | 2000-11-20 | 2007-06-27 | Smithkline Beecham Corporation | Novel compounds |
DK1354884T3 (da) * | 2000-12-28 | 2008-03-03 | Ono Pharmaceutical Co | Cyklopenta[d]pyrazolo[1,5-a]pyrimidinforbindelse som CRF-receptorantagonist |
GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
US20040097502A1 (en) * | 2001-02-02 | 2004-05-20 | Gellibert Francoise Jeanne | Pyrazoles as tgf inhibitors |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2002066462A1 (en) * | 2001-02-02 | 2002-08-29 | Glaxo Group Limited | Pyrazole derivatives against tgf overexpression |
CA2445568A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6727364B2 (en) * | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
GB0127433D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
ATE373000T1 (de) * | 2001-12-11 | 2007-09-15 | Smithkline Beecham Corp | Pyrazolopyridin-derivate als antiherpesmittel |
EP1511738A4 (en) * | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
DE60315677T2 (de) * | 2002-09-17 | 2008-06-05 | Eli Lilly And Co., Indianapolis | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
OA12928A (en) * | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGF) inhibitors. |
CN1681810A (zh) * | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物 |
US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
KR20060088537A (ko) | 2003-09-06 | 2006-08-04 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절자 |
-
2003
- 2003-05-09 UA UAA200503095A patent/UA80295C2/uk unknown
- 2003-09-05 GE GEAP20038727A patent/GEP20074125B/en unknown
- 2003-09-05 AU AU2003268447A patent/AU2003268447B2/en not_active Ceased
- 2003-09-05 NZ NZ539069A patent/NZ539069A/en unknown
- 2003-09-05 US US10/526,839 patent/US7691865B2/en not_active Expired - Fee Related
- 2003-09-05 CA CA002497970A patent/CA2497970A1/en not_active Abandoned
- 2003-09-05 RS YUP-2005/0200A patent/RS20050200A/sr unknown
- 2003-09-05 PL PL03375699A patent/PL375699A1/xx not_active Application Discontinuation
- 2003-09-05 BR BR0314053-9A patent/BR0314053A/pt not_active IP Right Cessation
- 2003-09-05 WO PCT/US2003/027722 patent/WO2004022054A1/en active Application Filing
- 2003-09-05 CN CNA038248670A patent/CN1694698A/zh active Pending
- 2003-09-05 JP JP2004534571A patent/JP2006502165A/ja active Pending
- 2003-09-05 KR KR1020057003874A patent/KR20050057235A/ko not_active Application Discontinuation
- 2003-09-05 EP EP03749412A patent/EP1551398A4/en not_active Withdrawn
- 2003-09-05 MX MXPA05002443A patent/MXPA05002443A/es active IP Right Grant
- 2003-09-05 EA EA200500450A patent/EA009441B1/ru not_active IP Right Cessation
- 2003-09-08 AR ARP030103250A patent/AR041207A1/es unknown
-
2005
- 2005-03-03 ZA ZA200501856A patent/ZA200501856B/en unknown
- 2005-03-04 IS IS7726A patent/IS7726A/is unknown
- 2005-03-04 IS IS7725A patent/IS7725A/is unknown
- 2005-03-21 NO NO20051503A patent/NO20051503D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL375699A1 (en) | 2005-12-12 |
US20060106033A1 (en) | 2006-05-18 |
CN1694698A (zh) | 2005-11-09 |
CA2497970A1 (en) | 2004-03-18 |
IS7725A (is) | 2005-03-04 |
NO20051503L (no) | 2005-03-21 |
EP1551398A1 (en) | 2005-07-13 |
NZ539069A (en) | 2007-03-30 |
WO2004022054A1 (en) | 2004-03-18 |
US7691865B2 (en) | 2010-04-06 |
AU2003268447B2 (en) | 2008-07-24 |
BR0314053A (pt) | 2005-07-19 |
IS7726A (is) | 2005-03-04 |
EA200500450A1 (ru) | 2005-08-25 |
RS20050200A (en) | 2007-08-03 |
AU2003268447A1 (en) | 2004-03-29 |
GEP20074125B (en) | 2007-06-11 |
EP1551398A4 (en) | 2006-06-07 |
UA80295C2 (en) | 2007-09-10 |
MXPA05002443A (es) | 2005-09-30 |
EA009441B1 (ru) | 2007-12-28 |
KR20050057235A (ko) | 2005-06-16 |
JP2006502165A (ja) | 2006-01-19 |
NO20051503D0 (no) | 2005-03-21 |
AR041207A1 (es) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501856B (en) | Pyrazolopyridines and methods of making and using the same | |
ZA200501853B (en) | Imidazolopyridines and methods of making and usingthe same. | |
JP6993985B2 (ja) | イソキノリン-3イル-カルボキサミドならびにその調製および使用の方法 | |
ZA200506408B (en) | Parazoles and methods of making and using the same | |
JP2006502164A5 (is) | ||
DK2017278T3 (en) | DIHYDROPYRAZOLOPYRIMIDINON DERIVATIVES | |
CA2620534C (en) | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | |
EP2571877B1 (en) | 1h-imidazo[4,5-c]quinolines | |
US20110059941A1 (en) | 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators | |
EP1786802A1 (en) | Pyrimidinylimidazoles as tgf-beta inhibitors | |
AU2009288399A1 (en) | Hedgehog pathway modulators | |
US20130315895A1 (en) | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET | |
AU2014259151A1 (en) | Quinazolinone derivatives useful as FGFR kinase modulators | |
EP2027113A1 (en) | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes | |
KR20150016595A (ko) | Fgfr 억제제로서의 프테리딘 | |
KR20090094299A (ko) | 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 | |
CA2531619A1 (en) | Biaryl piperazinyl-pyridine analogues | |
AU2005280167A1 (en) | Pyrimidinylpyrazoles as TGF-beta inhibitors | |
JP2006502165A5 (is) | ||
AU2014215991A1 (en) | Small molecule myristate inhibitors of bcr-abl and methods of use |